Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29970794 | 0.86 | HTT (0.65) | HTTDYRK1APPARAAPPLMNA | |
| SCHEMBL21154487 | 0.86 | HTT (0.65) | HTTDYRK1APPARAAPPLMNA | |
| SCHEMBL30917945 | 0.81 | DYRK1A (0.46) | HTTDYRK1APPARAAPPADORA1 | |
| SCHEMBL21154115 | 0.79 | SMN1; SMN2 (0.56) | HTTPPARALMNAMGAMGAA | |
| SCHEMBL5421955 | 0.79 | MAPT (0.53) | HTTAPPLMNAGAACYP1A2 | |
| SCHEMBL4512720 | 0.78 | HTT (0.63) | HTTAPPLMNAGPR183GAA | |
| SCHEMBL17836733 | 0.77 | DYRK1A (0.53) | HTTDYRK1APPARAAPPADORA1 | |
| SCHEMBL4510430 | 0.77 | HTT (0.61) | HTTAPPLMNAGPR183GAA | |
| SCHEMBL24782799 | 0.76 | HTT (0.49) | HTTAPPLMNAGAACYP1A2 | |
| SCHEMBL14288355 | 0.76 | HTT (0.49) | HTTLMNACYP1A2CYP2D6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631941-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| CN-118005624-B | Pyrimidine benzo five-membered ring CDK inhibitor and preparation method and application thereof | 中国药科大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-118146213-B | Benzothiazole pyrimidine amine DYRK2 inhibitor and preparation method and application thereof | 江苏天士力帝益药业有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024119866-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2024-06-13 | — | — | WO | disclosed |
| CN-118146213-A | Benzothiazole pyrimidine amine DYRK2 inhibitor and preparation method and application thereof | 江苏天士力帝益药业有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118005624-A | Pyrimidine benzo five-membered ring CDK inhibitor and preparation method and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| WO-2019233883-A1 | TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES | AC IMMUNE SA (CH) | 2019-12-12 | — | — | WO | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | HTT 18/4885DYRK1A 3415/4885PPARA 2281/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | HTT 23/4885DYRK1A 4167/4885PPARA 2348/4885 |
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CDK6, DYRK2, CDK16 | HTT 3374/4885DYRK1A 8/4885PPARA 3949/4885 |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | HTT 1519/4885DYRK1A 641/4885PPARA 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.